Key facts
- It has raised $33.0M; the latest was Accelerator/Incubator in Aug 2025.
- Notable investors include KB Investment, IMM Investment, Shinhan Venture Investment, Johnson & Johnson Innovation - JLABS, Kiwoom Investment — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Trioar
- ·The full record, as it builds
Funding rounds
No funding rounds for Trioar are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Trioar
Developer of drugs designed to improve the limitations of antibody therapeutics and antibody-drug conjugates. The company's drugs detect cancer lesions so that they are absorbed quickly and specifically target cancer cells while rapidly inducing cancer cell death, enabling healthcare companies to come up with medicine for patients and provide them with proper treatment.
- Sector
- Healthcare
- HQ
- Daejeon, South Korea
- Founded
- 2021
- Employees
- 22
- Website
- trioar.co.kr/
- Ownership
- Privately Held (backing)
Trioar doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Trioar shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Trioar in its N-PORT filings yet. We sweep new filings monthly.